Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Guided Therapeutics Q3 2026 Results: Net Loss of $720K, Loss Narrows

Guided Therapeutics reported a net loss of $1.8 million for the nine months ended September 30, 2026, compared to a $2.0 million loss in the prior year period. Revenue decreased significantly to $92,000 from $177,000 year-over-year, while the company continues to operate with a substantial stockholders' deficit of $6.1 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.10.1
Gross profit0.10.0
Profit before tax-0.7-0.7
Net income-0.7-0.7
EPS (diluted, $ a share)$-0.01$-0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+53.3%
Gross margin97.8%
Source

10-Q filed with the SEC, OTC: GTHP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Guided Therapeutics Inc: key numbers

Share price
$0.1100Close, Nov 13
Market cap
$10.8M
Shares outstanding
98.19MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.